Today: 13 June 2026
Bank of America stock slides after Wolfe downgrade as earnings clock ticks
7 January 2026
2 mins read

Bank of America stock slides after Wolfe downgrade as earnings clock ticks

New York, Jan 7, 2026, 13:06 ET — Regular session

  • BAC shares fall about 2% after Wolfe Research cuts its rating
  • Bank of America set to report quarterly results on Jan. 14
  • Traders eye Friday’s U.S. payrolls report for fresh rate clues

Bank of America Corporation shares fell nearly 2% on Wednesday after Wolfe Research downgraded the lender to “peer perform,” pointing to limited upside and a tougher setup for 2026 estimates. The stock was down 2.0% at $56.13 in midday trading. Investing.com UK

The Wolfe call lands as big banks head into earnings season with valuations already elevated after last year’s run. “We are taking some chips off the table,” Wolfe analyst Steven Chubak wrote, as investors brace for results from the largest U.S. lenders next week. Bloomberg.com

JPMorgan Chase is set to kick off bank earnings on Jan. 13, with Bank of America, Citigroup and Wells Fargo due a day later. “The fourth quarter shaped up to be a perfect recipe … for investment banking revenues,” said Stephen Biggar, a banking analyst at Argus Research, as dealmaking and trading activity improved. Reuters

Bank of America said it will report fourth-quarter 2025 results on Wednesday, Jan. 14, releasing the numbers at about 6:45 a.m. ET, followed by an investor call at 8:30 a.m. ET. The bank said supporting materials will be posted to its investor relations site, with a results 8-K also available through the SEC.

In a separate filing on Tuesday, the bank disclosed an accounting change for certain tax-related equity investments tied to affordable housing and renewable energy credits. Bank of America said the shift is mainly a reclassification between income statement lines, but it lowered retained earnings by $1.7 billion as of Sept. 30, 2025 and would have reduced its common equity tier 1 ratio — a key bank capital metric — by an estimated 13 basis points at that date.

Bank stocks also softened more broadly as investors digested weaker-than-expected U.S. labor reports and locked in gains after a three-session rally, while the wider market held near record levels. “The economic news sort of fueled a little bit of profit taking,” said Robert Pavlik, senior portfolio manager at Dakota Wealth, with the government’s December payrolls report due on Friday. Reuters

Beyond earnings, rate expectations remain the swing factor for Bank of America and its peers. Net interest income — what a bank earns on loans minus what it pays on deposits — can shift quickly when the curve moves, and the Fed’s next policy meeting is scheduled for Jan. 27-28.

The risk for bulls is that inflation and wages run hot enough to delay cuts, keeping funding costs higher for longer or cooling loan demand. Richmond Fed President Thomas Barkin said further rate moves will need to be “finely tuned” as policymakers balance inflation that remains above target against a labor market that has started to soften. Reuters

Next up: Friday’s payrolls data, then the opening wave of bank earnings starting Jan. 13, with Bank of America reporting on Jan. 14.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Previous Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none
Next Story

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

Go toTop